Summary Minutes of the 2nd Institutional Review Board Meeting in FY2020 (Expedited review)

Date: Friday, June 19, 2020, 10:00 to 11:35, 13:30 to 15:05

Place: Auditorium (Hiroshima) and the 3rd conference room (Nagasaki)

Participants: Dr. Kodama, Ms. Shinohara, Dr. Tanabe, Dr. Sugiyama, Ms. Dodo, and Mr. Fuchi

[Review of research involving human subjects]

	Department	Title of study	Review result	Summary minutes
1	Epidemiology	CR165 “Radiation risk for hematological malignancy incidence” (Dr. Mabuchi *et al.*)	Approved	●That opt-outs will be guaranteed and there will be a policy for selection of a proxy should be included on the RP and application form. ●That pathology materials and samples will be used for a pathologist’s review and personal information on paper documents will be masked should be included on the RP and application form. ●The accurate number of cases for the data should be included in the RP. ●The total number of data to be provided should be included on the RP and application form. The disposal method for the information at the recipient should be described in detail. ●Revise the title (in Japanese) to “Radiation risk for hematological malignancy incidence.” ●So that it is easier for the public to understand, the wording in the "Method of using samples/information" and "Samples/information items to be used or provided" sections of the information disclosure form (Form 1-5-2) should be revised.
2	Clinical Studies	CR164 “Evaluation of radiation-related changes in clonal hematopoiesis, inflammation, and atherosclerosis indicators among A-bomb survivors” (Dr. Nakamizo *et al.*)	Approved	●Informed consent forms used when existing samples/information were collected should be submitted. ●That cancer registry information may be used should be included on the RP and information disclosure form (Form 1-5-1). ●RP2-00 and RP4-02 should be mentioned in the RP. ●The "conflicts of interest" section of the RP should be revised to “No anticipated conflict of interest.” ●Items 8, 12, 14, 16 and 17 of the checklist (for RP) should be added to the RP.
3	Clinical Studies	Revisions to RP-A5-13 “The association between thyroid status and the progression of renal function over time” (Dr. Elzen *et al.*)”	Approved	●To the RP, add that the data already provided had been received before the effective date of the new guidelines.

*The RPs were approved by confirming that the aforementioned revisions would be duly made.

＊In order to prevent the spread of the new coronavirus, the committee members maintained sufficient distances from each other, and the meeting venues were regularly ventilated.